text:
Alain Beck
Senior Director, Biologics CMC and developability
Pierre Fabre Laboratories
Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories. He is associated editor of mAbs (www.tandfonline.com/loi/kmab20) and mAbDesign scientific advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology (dalotuzumab/IGF-1R licensed to Merck; telisotuzumab and telisotuzumab vedotin/cMet, licensed to AbbVie; h515H7/CXCR4 and W0101 ADC/IGF-1R), peptides and vaccines (BBG2Na/RSV, P40-ELA/ melanoma). He has published +210 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusions, protein scaffolds, structure/function relationships, stability, comparability and developability (h-index: 45; +7300 citations). He was involved in more than 260 scientific meetings (AIS, ASMS, BAS, CASSS, EAC, HPLC, IBC, IMSC, ISC, PEGS, SEP, WADC, WBC) as chairperson, invited plenary/ keynote speaker, panelist, moderator, advisor, and organizer as well as to meetings and workshops with regulatory agencies (ANSM, EMA, EDQM/PhEur, FDA, PEI, WHO). He was ranked 6/50 global antibody industry influencers (www.antibodysociety.org).
Day One
Tuesday 5th March 2019
17.30 | Chair's Closing Remarks
08.10 | Riding the ADC Rollercoaster: In-Depth Review of Current ADC Field, as well as Insights on Hotspots of Innovation
08.00 | Chair's Opening Remarks
Day Two
Wednesday 6th March 2019
17.00 | Chair's Closing Remarks
08.50 | Chair's Opening Remarks
Andreas Hald
Research Associate
Copenhagen University Hospital
In my present position, I perform basic research in antibody drug conjugate (ADC) targeting of cancers (sarcoma). My responsibilities include general experimental work (both in vivo and in vitro) as well as defining/choosing strategies for progressing our projects. The ultimate goal is to support and optimize a uPARAP targeting ADC, so it may become of interest for biotech/medical companies that have the capacity to take our research-drug into clinical development.
Antony Bigot
Section Head
Dr Antony Bigot holds a PhD in Organic Chemistry from The Orsay University (France). After a post-doctoral position at The Scripps Research Institute in San Diego with Pr K.C. Nicolaou, he joined Sanofi (at that time Rhône-Poulenc Rorer) in 1999 on Vitry-Sur-Seine site as Medicinal Chemist. He then successively hold different positions in Medicinal Chemistry (1999-2004), then in Chemical Process Development (2004-2016). Since July 2016, he his Head of Pre-Development Science Synthetic Chemistry France. His main focus are designing SMART synthesis of small-molecule payloads and linkers to be used in ADCs.
Arnaud Delobel
Director, Research and Development
Quality Assistance
Arnaud Delobel is the R&D Director at Quality Assistance. As the head of the R&D Department, he is responsible for supervising internal R&D projects, aiming at implementing new analytical technologies that will ultimately be provided by Quality Assistance to their customers. He is also supervising the work of Scientific Managers who identify market needs with input from the Management, Regulatory Affairs Manager and external experts, and from any relevant data gathered by Quality Assistance, and that are responsible for interpreting and translating this intelligence into developing new R&D services.
Arnaud Tiberghien
Scientist Medicinal Chemistry
After a master degree in organic chemistry in France, Arnaud began his career in oncology working under the supervision of Malcolm Stevens (inventor of temozolomide) at the University of Nottingham. He then joined the CRUK gene targeting group led by Prof David Thurston and Dr Philip Howard and obtained a PhD in medicinal chemistry from UCL. Arnaud was amongst the first employees to join Spirogen, where he helped establish the pyrrolobenzodiazepine ADC technology platform. Arnaud is Spirogen lead chemist on the tesirine program, originally developing the synthetic route, followed by management of manufacturing campaigns for Spirogen and its licensees. In this endeavour, a robust supply chain had to be established with contract manufacturing organisations to scale-up the 34 steps synthesis, eventually delivering quantities of GMP-material large enough to support multiple phase I clinical trials. Arnaud's current interests include ADC payload properties and design, as well as a broader understanding of the emerging rules governing the field of ADCs.
Brian Clark
Principal Consultant
GMP Operations Consulting
Brian Clark is Principal at GMP Operations Consulting, LLC, and provides interim executive leadership, CMC strategy, manufacturing and quality strategy and operational support to biopharmaceutical companies worldwide. GMP Operations Consulting focuses on biopharmaceuticals with additional expertise in regenerative medicine, cell therapies and antibody drug conjugates. Previously, Brian was at ImmunoGen Inc. from 2011 to 2016, most recently serving VP Manufacturing and Norwood Site Head and, prior to that, as Executive Director, Quality. Prior to joining ImmunoGen, Brian was an individual consultant for several years in his current practice. Brian previously served in senior Operations and Development leadership roles at Altus Pharmaceutical, Alkermes, Therion Biologics, Antigenics (now Agenus) and Genzyme Tissue Repair. Brian obtained his MBA in General Management from Boston University and his BS in Biology from the University of Massachusetts.
Workshop F
Monday 4th March
09.00 | Scale Up, Outsourcing & Managing Complex Supply Chains
Brian Mendelsohn
Director, Process Development & Tech Transfer
Day One
Tuesday 5th March 2019
16.30 | Development of a Novel Chemical Site-Specific ADC Conjugation Platform with Enhanced Therapeutic Window
Camille Martin
External R&D Director
Cathy Zhang
Senior Principal Scientist
Cathy Zhang is a Senior Principle Scientist in Oncology Research Unit at Pfizer (San Diego, California). Cathy leads a group focusing on developing preclinical tumor models and performing preclinical enabling studies for IND or NDA programs. She also works with internal and external partners to establish strategies toward patient stratification and novel combinations to aid clinical trial designs. Cathy has authored or co-authored over 20 peer-reviewed research articles in scientific journals.
Charles Dumontet
Professor of Hematology & Team Leader
Cancer Research Center Lyon
Charles Dumontet is a Team Leader at the Cancer Research Center Lyon. His group studied the mechanisms of action of monoclonal antibodies that are targeting cancer cells. We also study the mechanism of resistance towards these biomolecules in order to increase the activity of therapies based on monoclonal antibodies in patients with hematological malignancies or solid tumors.
Workshop B
Monday 4th March
09.00 | Conjugate Diversity: Past, Present & Future
Claudio Pozzoli
Chief Scientific Officer
Day Two
Wednesday 6th March 2019
12:30 | Lunch Seminar: Cerbios-Pharma and ADIENNE
David Bramhill
Bramhill Biological Consulting
Dr. Bramhill has over 20 years experience in biologics, both in large biopharma and startup biotech companies. He has experience in isolating and improving antibodies using phage display and is an inventor on library design techniques for small scaffolds. He also has experience in diverse expression systems for producing antibodies, antibody fragments and different scaffolds. He has taught numerous technical courses for over 10 years at international conferences.
Workshop A (Full Day)
Monday 4th March
9.00 | Primer Course: Introduction to the Design, Discovery & Development of ADCs (FULL DAY)
Dhaval Shah
Assistant Professor of Pharmaceutical Sciences
State University of New York at Buffalo
Prof. Dhaval K. Shah is an Associate Professor of Pharmaceutical Sciences at the State University of New York at Buffalo. Prior to becoming the faculty Prof. Shah served as a Principle Scientist in the 'Translational Research-Modeling & Simulation' group at Pfizer Inc. His research focuses on understanding the determinants for the absorption, distribution, metabolism, and elimination (ADME) of protein therapeutics. His lab uses the principles of Pharmacokinetics-Pharmacodynamics (PK-PD) Modeling & Simulation to support the discovery, clinical translation, and late phase development of novel biologics like engineered antibodies, multi-specific proteins, immuno-oncology agents, engineered T cells, and antibody-drug conjugates. He has developed several pioneering systems PK/PD models for ADCs, and continue to develop mechanism models to understand and improve pharmacological behavior of ADCs.
Workshop E
Monday $th March
13.00 | PK/PD Based Strategies to Improve the Therapeutic Index of ADCs
Deyarina Gonzalez
Associate Professor of Molecular Medicine
Swansea University Medical School
Deya's research focuses on biomarkers discovery and translational medicine in the areas of female infertility and gynaecological cancers. She has applied her expertise in inflammation, angiogenesis, vascular permeability, reproductive biology and cell to cell interactions to develop multicellular 3D models for use as tools in biomarker discovery and drug development. Her projects involve collaborations with the private sector to expedite validation of clinical diagnostic biomarkers and the development of new drug leads for targeted cancer therapy including Antibody Drug Conjugates and Exosomes. She is a co-PI of the Smart Expertise project CEAT-Cluster for Epigenomics and ADC therapeutics (£2.6M), where she leads the ADC programme. Deya is Chair of the Medical School Research Ethics and Governance and she also teaches within the Genetics & Biochemistry undergraduate and postgraduate Nanomedicine programmes at Swansea University
Day One
Tuesday 5th March 2019
08.40 | Preclinical Development of a RAGE ADC for Gynaecological Cancers
Douglas Leipold
Principal Researcher
Douglas is a Staff Scientific Research at Genentech. As a proven leader in the PK/PD department, Douglas provides leadership, strategic thinking and technical support for the pharmacokinetic, pharmacodynamic and laboratory assessment of drug candidates and marketed products. Douglas has led numerous teams and am passionate about leading cross-functional and multi-disciplinary teams in early stage characterization through IND and into clinical development.
Day One
Tuesday 5th March 2019
17.00 | Preclinical Pharmacokinetics & Pharmacodynamics of DCLL9718A: an Antibody Drug Conjugate for the Treatment of Acute Myeloid Leukaemia
Earl Albone
Senior Director, Biochemistry and Bioanalytical Development
EPAT, OBG, Eisai Inc
Dr. Albone is currently Director, Biochemistry Discovery at Morphotek, Inc., a wholly-owned subsidiary of Eisai, Inc. His group's research focuses on early-stage development of therapeutic antibodies and antibody-drug conjugates for oncologic applications, including development of unique site-specific conjugation platforms and novel payloads. He has 20 years of experience in biologics research in both large pharma and early-stage biotechnology firms. He received his BS in Chemistry and PhD in Biochemistry from the University of Rochester.
Eric Lacoste
Head, Bio-Organic, Chemistry Team
Eric Lacoste is ADC Team Leader and Head of the Bio-Organic lab within Sanofi. He has in charge the supervision of process development for Protein Conjugates to support research programs and up to commercial launch readiness .He also oversees cGMP manufacturing and is responsible for process transfer to internal partners or CMO. Eric Lacoste holds a PhD in Organic Chemistry and joined sanofi in2007 to develop ADC process research.
Gavin Bennett
Director, Project Leader
Bicycle Therapeutic
Gavin Bennett is Director, Project Leader at Bicycle Therapeutics in Cambridge, UK, responsible for the development of the BT5528 programme. Bicycle Therapeutics is developing novel constrained bicyclic peptide (Bicycle) peptides. One application of the technology is the development of Bicycle Drug Conjugates for Oncology, allowing targeted delivery of cytotoxic payloads. Gavin has a PhD in Pharmacology from King's College London and has worked across therapeutic areas, including oncology, inflammation and CNS disease, developing small molecules, large molecules (antibodies) and now mid‐sized molecules (bicyclic peptides). Prior to Bicycle Therapeutics, Gavin led preclinical and pharmacology programmes for companies such as Cellzome, UCB‐Celltech, RhonePoulenc Rorer.
Giorgio Salciarini
Technical Business Development Manager
BSP Pharmaceuticals
Giorgio is part of the Business Unit, with responsibility of coordinating Business Development activities He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager than moved to BD in 2014. Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth. Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia.
Greg Thurber
Assistant Professor
University of Michigan
Greg Thurber is the Assistant Professor of Chemical and Biomedical Engineering at the University of Michigan. Prior to joining the University of Michigan in 2014 Greg was an Instructure at the Center for Systems Biology and Research Fellow at Harvard Medical School. Greg received his PhD in Chemical Engineering at Massachusetts Institute of Technology.
Workshop D
Monday 4th March
09.00 | Designing Effective ADCs through Pharmacokinetic Modelling and PK/PD Experiments
Day Two
Wednesday 6th March 2019
16.30 | Single-Cell Pharmacokinetics & Pharmacodynamics of Biologics: Designing Effective Antibody Drug Conjugates & Checkpoint Inhibitors
Hadi Falahatpisheh
Head of Toxicology
Abbvie Stemcentrx
DABT Board-certified toxicologist with ~ 20 years experience in academic research and Drug Discovery/Development. Expertise in various drug modalities (small molecule, mAb, antibody drug conjugate, bispecific T-cell engagers) in various therapeutic areas (Oncology, immuno-oncology, infectious disease, and vaccine). Successfully led nonclinical development of several anti-cancer agents from the early discovery to clinical proof of concept and registrations (BLA.) Extensive involvement in discovering novel targeted therapeutics in oncology and immunotherapy and nonclinical portfolio management.
Hans-Georg Lerchen
Principal Scientist Protein Engineering
Hans-Georg Lerchen is a Principal Scientist in the Medicinal Chemistry unit of Bayer AG, Pharmaceuticals Division. With a 28 years background in MedChem he is author or co-author of 73 patents or patent applications and 16 publications. His current research focus is drug delivery systems, prodrugs and in particular antibody drug conjugates.
Hong Wang
Associate Director & Senior Scientist, Development Toxicology
Board certified toxicologist with 16+ years of experience in biotechnology/pharmaceutical industry. Experienced in nonclinical safety development of large and small molecules of all development stages (discovery to marketing approval). Successful track record of regulatory filings and interactions. Experienced in leading multidisciplinary project teams.Specialties: Preclinical safety assessment of small and large molecules in immunology, oncology and cancer immunotherapy areas; early safety assessment of novel targets and safety de-risking; cardiovascular safety
Ian Schwartz
Technology Consultant, Bioconjugation
Sartorius Stedim
Ian Schwartz joined Sartorius Stedim Biotech in December 2016 and is Sartorius' global bioconjugate technical subject matter expert. Ian has over 14 years of experience in the biotechnology industry and specializes in bioconjugate process development, technology transfer and manufacturing. Ian began his career at Biogen and has moved onto positions of increasing responsibility at ImmunoGen, MedImmune and most recently Agensy, a former affiliate of Astellas Pharmaceuticals, where he started up and led the ADC process development, tech transfer, and manufacturing support group for a number of years. With more than 14 years in the biotechnology industry, Ian supports, in his current role, process development and scale up of bioconjugate processes for Sartorius' customers and is Sartorius' internal bioconjugate subject matter expert liaison to R&D.
Iontcho Vlahov
Vice President
Dr. Vlahov received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany. Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov's main scientific interest is the design and synthesis of complex biologically active molecules. In the past 18 years, as the head of Endocyte's Discovery Chemistry department, Dr. Vlahov has been active in the discovery of personalized targeted therapies of cancer and autoimmune diseases. His research efforts are aimed toward discovery of novel small molecule drug conjugates, linker systems, spacer units, and highly potent warheads. To date, these programs led to the development of seven clinically investigated agents. Dr. Vlahov is an Alexander von Humboldt Fellow and recipient of George and Christine Sosnovsky Award for Cancer Research.
Jonas Helma
Project Leader, Biology
Ludwig Maximillian's University
Jonas Helma is a Scientist at the Ludwig Maximillian's University in Munich. Jonas research focus's on cell-based assay development with recombinant antibodies, protein engineering, technology development, site-specific antibody conjugates, IP management, lecturing.
Justin Mason-Home
HPAPI Project Services Limited
Justin Mason-Home is an organic chemist with extensive health, safety, environmental and chemical engineering experience in senior technical, legal and commercial aspects of the pharmaceutical, biochemical, chemical and other industries. He has held senior positions and worked globally in potent biopharmaceutical occupational health and safety global environmental consulting, board level positions in a biotechnology company and corporate environmental management. Mr Mason-Home has worked on multiple ADC projects and specialises in technical complex and strategic projects, including unique experience in managing sensitive highly potent and toxic biopharmaceutical compound matters.
Workshop G
Monday 4th March
13.00 | Occupational Health & Safety in Delivering ADC Projects
Jutta Wanner
Chief Scientific Officer
Kasper Møller
General Manager
Kathryn Pugh
Analytical Chemist
Kathryn joined Spirogen in February 2018 as an analytical scientist where she develops and delivers analytical and QC services for small molecules and ADCs. This includes the development of assays for pharmacokinetics, enzyme activity, DNA-PBD (pyrrolobenzodiazepines) interaction and peptide mapping. Kathryn gained experience in proteomics and quantitative LC-MS/MS during her postdoc in the Target Discovery Institute at the University of Oxford (2014-2018) working with Paul Brennan, Kilian Huber and Benedikt Kessler. Prior to this, Kathryn completed her PhD in Chemical Biology and MChem in Pharmaceutical Chemistry at the University of Leicester. Under the supervision of Paul Cullis, Glenn Burley and Andrew Tobin, her PhD research focused on developing chemical tools to understand several kinases in the P. falciparum parasite.
Letrishka Anthony
Senior Analyst, Beacon
Hanson Wade
Day Two
Wednesday 6th March 2019
16.00 | Review of the ADC Clinical Pipeline
Lisa McDermott
Head of Process and Analytical Development
Ling Xu
Principal Scientist
Mersana Therapeutics
Dr. Ling Xu obtained her Ph.D. from University of Colorado at Boulder, where she was trained as an enzymologist. She has over 17 years' experience with mass spectrometry application in the areas of characterization and quantification of both small and large molecules. She worked as a Senior Research Associate at a proteomic mass spectrometry central lab at University of Toronto for five years. She has been working at Millennium Pharmaceutical/Takeda Boston for over nine years leading bioanalysis of antibody drug conjugates. Before that, she did research at Brigham Woman Hospital /Harvard School of Medicine for around a year as a Research Associate on structural elucidation of bioactive small molecules that activate the resolution of acute inflammation. Dr. Ling Xu joined Mersana Therapeutics, Inc. in 2017.
Mark Frigerio
Director of Chemistry
UK Abzena
Mary Robinette
Principal Project Engineer
Mary Robinette has over 25 years of process engineering experience in the chemical and pharmaceutical industry. Mary started her career with MilliporeSigma 14 years ago as project engineer supporting pharmaceutical new products. Mary is responsible for new process scale-up, process equipment/facility design and capital project management. Mary has been the lead process engineer for design, construction and commissioning of our ADC Commercial facility opened in 2015. Mary holds a BS in Chemical Engineering and is certified as Project Management Professional (PMP).
Matthias Winzer
Associate Director Parenteral Development
Merck KGaA
Matthias Winzer, Associate Director Parenteral Development at Merck/Germany. Matthias is biotechnology engineer by training. In his current role he is head of the early phase formulation development team in Mercks healthcare division. Over the last years he has worked in discovery and early development projects on formulation and characterization of injectables as principle scientist, CMC-leader and associate director. Matthias has also served as a link between discovery and early clinical supply of biologics and ADCs. He filled several other positions at Merck before such as development engineer in late stage formulation and process development of biologics, biotech CMO manager for a marketed antibody brand and spent an extended period at the swiss Merck site in Corsier-sur-Vevey as project manager biotech process science. Before he joined Merck in 2001, Matthias worked at the biotech start-up ProThera/Germany (meanwhile acquired as Wacker-Biotech) with a focus on characterization of therapeutic recombinant proteins, at the Hans-Knoell-Institute/Germany in microbial biofilm research and at BASF Ludwigshafen/Germany in the field of PAT technologies for large scale fermentation processes.
Melanie Derde
Head of Analytical, Bioconjugation
Experience: Melanie joined Novasep in March 2016. She has 8 years of experience in biologicals analysis, protein purification and production of bioactive proteins, ADC analytical labs set up and ADCs analysis. Skills: Chromatography (HPLC-SEC/IEX/HIC/RP, GC, FPLC, method development), fluorimetry, flow cytometry, spectroscopy (UV/VIS, CD, IR), protein/ADC mass spectrometry, electrophoresis, ELISA, microscopy, microbiology, cell culture and bioburden.
Marcus Boehme
Head of Research & Development
Marcus Böhme studied biochemistry at the Martin-Luther-University in Halle and performs his PhD thesis in the Group of Professor Bordusa, working on the reprogramming and optimization of proteases for synthetic applications. In 2015 he joined BTI as Head of Research & Development, where he focuses on the development of the company's novel TrypCo® technology, a versatile enzyme-based conjugation platform for the generation of site-specific ADC´s. He is responsible for the enzyme engineering part in terms of generating enzyme candidates with excellent synthesis properties as well as the development and characterization of ADC´s generated by TrypCo® technology.
Nancy Levin
Vice President, Development
Nancy Levin joined Triphase in 2015 with more than 20 years' experience in the biotechnology industry, and technical expertise in clinical and translational pharmacology and nonclinical development. Nancy was Vice President of Therapeutics Product Design Group at Intrexon Corporation (2013-2014), where she oversaw the conception and development of novel therapeutic partnering opportunities enabled by Intrexon's proprietary cell- and DNA-based technologies. Prior to this, Nancy held positions of increasing responsibility at Pfizer (CovX Research, 2005-2013), X-Ceptor Therapeutics (2003-2004), MitoKor (2001-2003), and Trega Biosciences (1999-2001). Nancy's biotechnology experience began at Genentech (1993-1996), followed by Amgen (1996-1999), where she led multiple discovery and target validation projects. Her breadth of therapeutic area expertise includes oncology, metabolic and cardiovascular diseases, dermatology, inflammation, endocrinology, and rare/ultra-rare genetic diseases. She has led programs from discovery into clinical proof-of-concept employing multiple therapeutic modalities including small molecules, antibody-drug and -peptide conjugates, peptides, proteins, and antibodies. She earned a Ph.D. in Endocrinology at the University of California San Francisco, followed by post-doctoral training in the Fishberg Research Center for Neurobiology at The Mount Sinai School of Medicine in New York, NY.
Nomalie Jaya
Principal Scientist
Seattle Genetics, Inc
Nomalie Jaya received her Ph.D. in Biochemistry and Molecular Biophysics from the University of Arizona where she studied protein-protein interactions between molecular chaperones and their substrates. She worked at Corixa Corp. for 6 + years in the Analytical Biochemistry dept. prior to joining Seattle Genetics as a Characterization Scientist. Currently she leads the Capillary Electrophoresis group within the Analytical Sciences dept. She has served as the Analytical Lead for both early and late phase clinical programs. Her technical expertise is primarily in physicochemical methods development, and product characterization including mAbs and antibody-drug conjugates (ADCs).
Pedro Cal
Post-Doctoral Fellow
University of Lisbon (Instituto de Medicina Molecular)
Pedro MSD Cal has a PharmD (2010) and PhD in Pharmaceutical Sciences (2014). He is an expert in Chemical Biology with nearly 10 years of experience working in different universities and institutions (University of Lisbon, University College of London and University of Cambridge). He has nearly 20 publications, leading to about 800 citations, 2 book chapters, 2 patent applications and a h-index of 12. Recently he is interested on technology transfer/science entrepreneurship and he is part of a team of researchers that is about to spin-off some of the research that our group is developing at Gonçalo Bernardes' laboratories
Day Two
Wednesday 6th March 2019
09.00 | Exploring Different Routes to Generate Homogenous ADCs
Peter Bach
Director, Nonclinical Development
BioPharmaLogic Consulting
Peter Bach has worked in biopharmaceutical and CRO industries, where he has been responsible for candidate drug selection, building nonclinical strategy that lead to numerous FTIH packages, and toxicology studies to support Phases II and III clinical studies. He has also been closely involved in the associated interacts with Regulatory Agencies (across a number of therapeutic areas for biologicals, NCEs and devices) that lead to successful licensing. As an academic he contributed to the mechanistic understanding of toxicological changes in the kidney, using an array of in vivo and in vitro techniques. These published studies were completed by a multinational research and post-graduate group, using grant support from industry, and national and international research funding agencies and charities. Peter also ran international symposia and several post-graduate training courses.
Phillip Howard
Chief Scientific Officer
Dr Howard is a Founding Scientist and Chief Scientific Officer at Spirogen. He has been conducting research into the pyrrolobenzodiazepine (PBD) family of antitumor antibiotics for twenty years in both academia and industry. Philip has worked as a part of a multi-disciplinary team, supported by Cancer Research UK and Spirogen, on the synthesis, biological evaluation and development of the PBD dimers. Since 2008 he has been working on the development of the PBDs as payloads for antibody-drug conjugate therapy with a number of leading companies including, Seattle Genetics, Stemcentrx, ADC Therapeutics, Genentech, Regeneron and Tanabe Research Laboratories USA Inc. Dr Howard designed the tesirine payload (SG3249) and the warhead SG3132 released by the talirine payload. His work at MedImmune is focused on the further development of their PBD-ADC platform. At the time of writing, more than 12 PBD-ADCs, arising from Spirogen collaborations, are the subject of Phase I, Phase II, and Phase III clinical trials.
Kasper Møller
Rachel Forfar
Senior Scientist
Rakesh Dixit
Vice President & Global Head, Biologics
Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since 1992. Rakesh served as a Senior Toxicologist with Midwest Research Institute between 1987 and 1992. In December 1992, Rakesh joined the Department of Safety Assessment, Merck and Co., Inc, West Point, PA where he served in various management positions. During his about 14 years with Merck, Rakesh contributed to the successful filings of many blockbuster drugs. For about a year, Rakesh was associated with Johnson and Johnson PRD, La Jolla/Alza as Senior Director of Toxicology. In Aug 2006, Rakesh joined MedImmune, Inc. (an AstraZeneca Biologics company) as Senior Director (R &D) & Global Head of Biologics Safety Assessment, Experimental Pathology, and Laboratory Animal Medicine. In his current position as a Vice President of R &D since 2010, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines. Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings. Rakesh is one of the most invited speakers in the biotechnology industry. Rakesh's areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity. Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck. Rakesh a recognized expert in safety and pharmacology biomarkers and their applications.. Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015. Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.
Day One
Tuesday 5th March 2019
09.10 | Keynote: Lessons Learned from the Successful & Failed ADCs in Cancer Treatment: Moving Forward & Creating the Best Magic Bullets
Rebecca Mosher
Executive Director, Translational Medicine
Mersana Therapeutics
Rebecca Mosher is Executive Director, Translational Medicine at Mersana Therapeutics, where she has worked since 2016. She trained as a pathologist and has worked in the area of biomarkers and translational research at large and small companies.
Reza Safaei
Head of Global Medial Affairs
Nordic Nanovector
Dr. Safaei brings extensive experience in the development and commercialisation of novel therapeutics for haematological and solid cancers, gained with several world-leading biopharmaceutical companies. In his current role, Dr. Safaei holds the position of Head of Global Medical Affairs at Nordic Nanovector (NNV) where he is responsible for building a team of field-based Medical Science Liaisons (MSL) in the US and Europe, developing strong relationships with global experts and partnerships with clinical centres of excellence for non-Hodgkin's lymphoma (NHL), as well as designing and implementing medical education programmes to raise awareness of Nordic Nanovector's technology and Betalutin® prior to launch. Prior to joining NNV he was the Head of Medical Affairs Europe for Seattle Genetics and managed medical affairs and clinical development activities of pipeline products in solid and liquid cancers. Prior to this, Dr. Safaei served as Director, Medical Development, Immuno-Oncology and Scientific Communications, Haematology at AMGEN Europe. Dr. Safaei is trained in Internal Medicine and holds a Medical Degree from the University of Goettingen, Germany.
Scott Miller
Senior Scientific Advisor
Sibylle Heidelberger
Sr Support Specialist
Sibylle Heidelberger became interested in mass spectrometry while doing her master's degree in Canada before relocating to London, UK to do her PhD at the University of London, School of Pharmacy. Her focus for her PhD was proteomics and biopharma characterization towards drug development. Sibylle joined SCIEX in 2013 and has been working as a support specialist in OMICS and BioPharma.
Day One
Tuesday 5th March 2019
12.30 | Lunch Seminar: Fast, Easy and Accurate DAR Measurement using SCIEX X500B QTOF System and BioPharmaView™ Software
Steve Coats
VP R&D and Product Development
Steve Coats serves as AstraZeneca/MedImmune's VP R&D and Product Development Team Leader. His work focuses on interacting with external investigators to initiate clinical trials that are investigator led at academic institutes. Dr. Coats is also a product development team leader where he leads oncology project teams in early phase 1 and phase II clinical development for MedImmune's antibody drug conjugates and immune-oncology programs. Prior to joining MedImmune in 2005, Dr. Coats worked at Amgen, Inc. starting in 1996 and helped initially set up a cell cycle group and then became one of the first scientists in the newly formed cancer biology department. Dr. Coats earned his bachelor's degree in zoology from the University of New Hampshire in 1985. Following his undergraduate degree, he worked as a research assistant for three years in the pulmonary department at Beth Israel Hospital and Children's Hospital in Boston. He earned his Ph.D. in molecular and cell Biology in 1993 Vanderbilt University's Department of Cell Biology. The focus of his graduate work was on the role that PDGF receptors and ligands play in regulating signal transduction pathways and the cell cycle. He continued his cell cycle research during his post-doctoral work from 1993-1996 at the Fred Hutchinson Cancer Research Center in Seattle. While at the Fred Hutchinson Cancer Center he investigated the role that cyclin-CDK complexes play in regulating G1/S and G2/M transition points and he focused much of his research on examining the regulation of the cell cycle by the CDK inhibitor p27Kip1.
Stefano Porzio
QC Head
Day Two
Wednesday 6th March 2019
12:30 | Lunch Seminar: Cerbios-Pharma and ADIENNE
Sylvain Huille
Senior Scientist, Bio Development
Senior Scientist in BioDevelopment Sanofi R&D, previously Head of the formulation group at Sanofi Vitry from 2011 to 2018. Worked 6 years at LFB Biotech (2006-2011) in charge of the innovation platform for drug delivery and head of the formulation dept. Previously, held various positions at Flamel Technologies (13 years) as project leader and pilot unit manager. Co-inventor of Medusa® technology for sustained release of proteins. Ph.D in material science from University of Montpellier, France / Engineer in chemistry from the Ecole Nationale Superieure de Chimie de Paris, France.
Thomas Kofoed
CEO and Co-Founder
Day One
Tuesday 5th March 2019
12.30 | Lunch Seminar: Fast, Easy and Accurate DAR Measurement using SCIEX X500B QTOF System and BioPharmaView™ Software
Ulf Grawunder
Ulf Grawunder is CEO of NBE-Therapeutics, a Swiss Biotech company that he founded in 2012 and which focuses on the development of "next-generation" antibody-drug conjugates for cancer therapy. Prior to that, Ulf had co-founded 4-Antibody in 2004, a Swiss therapeutic antibody engineering company, where he initially served as CEO and later as CSO, until the company was sold to US-based Agenus. Ulf is a Biochemist who did his PhD in the area of B cell Immunology at the Basel Institute for Immunology. After this he did several years of post-doctoral research at Washington University School of Medicine, St. Louis, and the University of Southern California, Los Angeles. After that he returned to Europe to continue research as principal investigator at the Basel Institute for Immunology, and the University of Basel, Switzerland, before he started his first Biotech company, 4-Antibody. Ulf also holds a Diploma of Technology Entrepreneurship from the University St. Gallen, School of Business, Switzerland (HSG, Hochschule St. Gallen), and he is part if the teaching faculty of the European Center for Pharmaceutical Medicine (ECPM) at the University of Basel, Switzerland. Ulf is advisor of a number of national and international organizations, including the scientific advisory board of the Bavarian Immunotherapies Network, BayImmuNet, Germany (www.bayimmunet.de), the jury of Venturekick, Switzerland (http://www.venturekick.ch), and the Board of the Swiss Biotech Association (SBA, www.swissbiotech.org).
William Goundry
Associate Principal Scientist
Following his D.Phil in organic synthesis at Oxford University and Post Doc at Indiana University Will joined AZ at Macclesfield in 2006. He has developed a strong track record in process design and scale up working from grams to tonnes, including biocatalysis and flow chemistry. For the last four years he has been working in New Modalities and he is currently working on AstraZeneca's antibody drug conjugate (ADC) platform, with accountability for early phase payload synthesis. In this role he is developing the commercial routes and processes for ADC payloads, whilst supporting the manufacture of clinical trial material. He is an Honorary Lecturer at the University of Manchester in the Division of Pharmacy.
William Olson
Vice President, Therapeutic Proteins
Regeneron Pharmaceuticals
For the past 5 years, William Olson has served as Vice President, Therapeutic Proteins at Regeneron Pharmaceuticals. A primary area of responsibility is to generate novel monoclonal antibodies as potential new therapeutic product candidates using the VelocImmune mouse platform. He also spearheads efforts to conjugate VelocImmune antibodies with small-molecule drugs and positron-emitting isotopes for therapy and molecular imaging. His prior industry experience includes Progenics Pharmaceuticals, Johnson & Johnson and MicroGeneSys. He received his doctoral training at the Massachusetts Institute of Technology.
Day Two
Wednesday 6th March 2019
09.30 | Cytotoxic & Steroid ADCs for Cancer & Inflammation
Yiqing Feng
Senior Research Fellow
Eli Lilly
Yiqing Feng received her Ph.D. degree in Biophysics from University of Pennsylvania and completed a postdoctoral research program at University of Illinois at Urbana-Champaign. She has since worked at Monsanto, Pharmacia, Pfizer, and Centocor/Janssen/J&J before joining Eli Lilly and company. Dr. Feng is currently in Lilly Biotech to discover innovative biotherapeutics in order to improve quality of life for patients.


text:
Erin moved to London to pursue a career in acting and to begin studying drama at Queen Mary University of London. Roles include the short films 'Unforgettable', 'Performance' and 'Extra Time' (2015) the latter of which has recently become an award winning film.
Her passion for music, singing and dancing has led her to explore every part of the theatre. In 2015, she was the Assistant Musical Director for 'The King and I' (The Riverhead Theatre) and 'Oliver' (The Embassy Theatre) and she assisted with the singing coaching and acted in productions of 'Fame' and 'Footloose' (2011 & 2012 respectively) at The Regent Theatre, Stoke-on-Trent.
For Proforca Theatre Company, Erin was Musical Director / Assistant Director for "Saucy Jack & The Space Vixens" (Nov 2016) and Producer for the workshop production of "Feel" (2017)
We're delighted to welcome our very own "Triple Threat" to her first acting role with Proforca Theatre Company.
Twitter: @eoread7

subset: commoncrawl


text:
When Aftermarket leads the way
One of the most attractive SUVs on sale today, the new Range Rover Velar looks set to make many conquest sales for the iconic British marque. Bridging the gap between the Evoque and the Range Rover Sport, the Velar impresses with its sleek lines and dynamic driving experience.
Lumma Design sees the Velar as a prime candidate for a wealth of personalisation, and their first step gives it an even more expressive self-confident look with this wide body CLR GT package, made from high quality PU-RIM plastics.
The wide wheel arches are most distinctive and eye catching part of the conversion and add 50mm to each side of the Velar's overall width. The wide body look is supplemented by a prominent new front bumper, which features an integrated spoiler and Cup air splitter that give the Velar a more aggressive face and help to reduce aerodynamic lift at speed.
Contoured side skirts with horizontal blades that follow the line of the air splitter visually flesh out the area between the wide arches, and give the car a more grounded look. Meanwhile the new front grille and large bonnet air intake scoops seen on the design concept drawings last year add to the more sporting appearance.
The conversion is completed by the Lumma Design rear apron, whicl incorporates an integrated diffuser flanked by quad exhaust outlet covers. Above the waistline the three-piece tailgate and roofline rear spoiler help to reduce drag by smoothening out the departing airflow.
To fill out the big wheel arches, Lumma Design offers wheel and tyre packages in 22 and 23-inch sizes. The Lumma CLR LN 1 and Lumma CLR Racing alloy wheel designs, sized 12.0J x 22-inch are paired with 305/35ZR22 Michelin tyres. lf these are not sufficiently large you can order 11.0J x 23-inch Lumma CLR 23 GT alloywheels wrapped in 305/3oZR23 Continental rubber. As an option Lumma Design can provide appropriate wheel spacers to achieve the right offsets for these wheel/tyre combinations.
Real carbon-fibre looks technical and is in trend. Lumma Design offers a raft of parts made of, respectively with a surface look of real carbon-fibre for the Velar. The front and door design panels, sport front grille, Cup spoiler lip, front wings, bonnet panels, wing mirror caps, rear spoiler lip, rear diffuser, are all available as carbon version.
In addition to a sport steering wheel, the interior customisation program includes an aluminium pedal set as well as a floor and boot carpet mats embroidered with the Lumma Design logo.
Photos: Lumma Design
… Read more in AUTOMOTIV Issue #13
GET THE APP NOW – for FREE!


text: An easy route in the realm of transportation is called hoverboard for sale available to be purchased. It's an individual transportation having electric versatility which makes long separations too short. Utilizing a float board for transport is yet sufficiently sheltered as it is made with unique and hard materials. Late present day sheets are a tiny bit costly then old ones however gives you the assurance of wellbeing and life then the more established less expensive ones. We offer you the substantial guarantee and certification of our item. Try not to run with the shabby guarantee deal in advertise. As they don't change the item or back their certification. Additionally their sheets are excessively risky for transports. Remember while obtaining a board request the assurance of both the board and the battery. We gives you full certification of creativity and repairing.


text:
President Trump will not be interviewed as part of Special Counsel Robert Mueller's Russia probe, according to former Trump lawyer and U.S. attorney Joseph diGenova, who told Fox News Sunday that the investigation is now in "bad faith."
"The president will not sit down for an interview because this investigation has reached a level of bad faith," said diGenova "This is no longer a good faith investigation."
Joe diGenova: "The president will not sit down for an interview because this investigation has now reached the level of bad faith, this is no longer a good faith investigation." #FoxNewsSunday https://t.co/F6gn4EkMZJ pic.twitter.com/LD09KWXSNl
— Fox News (@FoxNews) May 6, 2018
Yesterday we noted the intense courtroom battle which played out on Friday between Judge Ellis and Mueller attorney Michael Dreeben in which Ellis put the Special Counsel in its place six ways from Sunday during a motion-for-dismissal hearing – giving prosecutors two weeks to produce evidence that Manafort was colluding with the Russians.
That is what elicited Judge Ellis's response that we don't want "unfettered power."
Judge Ellis continues, saying he's not going to be persuaded that Mueller has "unlimited powers to do anything" Mueller wants. pic.twitter.com/rysP4lIH9x
— Techno Fog (@Techno_Fog) May 5, 2018
Joe diGenova on Manafort raid: "Bob Mueller should be ashamed of himself to allow that to happen on his watch." #FoxNewsSunday https://t.co/F6gn4EkMZJ pic.twitter.com/fkyWwzYg4S
— Fox News (@FoxNews) May 6, 2018
President Trump has repeatedly expressed a willingness to testify in front of the Special Counsel, mentioning as recently as last week "I would love to speak… I would love to go through with it, if I thought it was fair to override my lawyers."
Both diGenova and Harvard Law professor Alan Dershowitz have dinged Rudy Giuliani over comments made last week that Trump reimbursed his personal attorney, Michael Cohen, for a $130,000 payment to adult film star Stormy Daniels.
🚨 Giuliani says Trump repaid Cohen the $130,000 used as hush money for Stormy Daniels pic.twitter.com/pqNtZthgwf
— Jon Passantino (@passantino) May 3, 2018
DiGenova says that Giuliani's comments are a "nothing buger," that serve "no useful purpose in terms of the facts."
"If it is a purely personal matter, which this clearly has to be, it doesn't matter what its relationship was to the timetable in a campaign," –Joe diGenova
Giuliani has since been making the media rounds trying to smooth out and clarify his comments – with the grand takeway being that the payments to Daniels (real name Stephanie Clifford) were perfectly legal.
Alan Dershowitz, meanwhile, told NBC's Meet the Press on Sunday that Giuliani's comments (whether intentional or not) "plays into the hands of Mueller's tactic to try at any cost … to find technical violations against lower-ranking people so that they can be squeezed."
The Harvard Law professor emeritus also said that Trump's team is "admitting to enough that warrants scrutiny," and that it's been a "bad week for both sides."


text:
An interesting piece by Willard Foxton in the Telegraph about how retailers use loyalty cards – and how they're much more useful for tracking disloyal customers than rewarding the most loyal.
Foxton has a Starbucks' example – you're more likely to receive vouchers offering you freebies if you're buy there irregularly than you are if you go in every day – but the same is true of most major retailers who run these schemes; the data allow segmentation of customer bases and targeting of promotions. And why bother giving the best deals to people who are going to buy from you anyway?
Subscription marketers have done this sort of thing for years of course. We do ridiculously cheap trial offers to lure in new customers, offer better renewal prices to first-time renewers than we do to our most longstanding subscribers and, if you should allow your subscription to lapse, you'll get discounted offers galore thrown at you.
And of course it seems to make sense; loyal customers (repeat renewers) will pay more, so why shouldn't a publisher exploit this fact to raise the subs yield and boost the lifetime value? It subsidises the acquisition efforts and helps attract new subscribers. The subs director's happy, the finance director's happy, the new subscriber is happy. The only person being stiffed is the long term subscriber.
This is becoming less and less sustainable. In olden days (say 10 years ago) you could keep the best subs offers more or less hidden – insert cards in newsstand copies only, say, or harsh dedupe rules to make sure your direct mail didn't go near existing subscribers – but that's not the case online. If I shop around for the best renewal quote for my house insurance, why wouldn't I do the same when the magazine subscription renewal arrives in my inbox?
And once I do this there's a chance you'll lose me through your direct renewal channel; I'll see a better deal on your main website, or visit a third party vendor, or go through a cash back site.
Or, because I think you're ripping me off by trying to charge me a higher price than everyone else, the loyalty I feel to your magazine will disappear and I won't bother renewing at all.
What are your renewal rates by age of sub? What's your subs churn? How many 'new' subscribers are really existing ones coming through different channels? How have these figures changed over the past few years?
And the most important question: what are you going to do about it?


text:
These events bring together clever, skilled fixer volunteers to help others fix broken household items. Can you mend a seam on a shirt? Do you know how to do a "darn" good job patching a knitted sweater? How about troubleshooting a lamp, vacuum or blender? Whether the answer is yes or no, please join us. We also need volunteers to help manage the registration table, talk with attendees, assist the fixer volunteers, etc
Contact: Lisa Clifton (Class 40) firstname.lastname@example.com


text:
Child Focused Parenting
Child Focused Parenting As a mom, I don't know how I could ever be anything BUT Child-Focused. When my babies were little babies, I distinctly remember thinking - "have I talked to an adult this week that isn't my husband or mom?" I stuttered because I was out of practice.
Child Focused Parenting
When was the last time I showered? (without a kid) Got my nails done? (without a kid) Got my hair cut? (without a kid).
I've cancelled date nights with my husband, I missed a Lady Gaga concert, watched endless Yo Gabba Gabba's, cancelled eye doctor appointments, driven to the gym and turned around - because of being Child - Focused.
I know. "In order to take care of everyone else, you have to take care of yourself." Everyone says that, women especially. It is a mantra that rings in all moms ears, reminding them to get that long overdue massage, make a lunch date with a friend, or go see a movie. And, I think could be the reason we have "Mom Guilt."
How could I not be Child-Focused?
Our Play + Explore Classes are that - Child Focused Parenting. Because as moms, that's what we are, and that is how we connect most with our children. We take the essence of where your kiddo is, in that very moment, and experience their world through their eyes. This means PLAY! Depending on each developmental stage, each child is going through his own process - sitting up for the first time, wanting to crawl, learning to share. It is all happening in live time! By being Child-Focused, we can better understand how our kids are processing and dealing with these mild stressors. It gives us insight into our kiddo's personalities by getting down on their level and playing. We best support them emotionally, when we are Child - Focused.
Children are nothing but Child-Focused. Emotionally, the world is all about them! They all experience the world on a multi-dimensional level. Touch, taste, sound, smell, and sight.
Each Play + Explore class highlights each of these senses - and then some. A little bit of yoga, structured movement, sensory play, singing and dancing. And, we do a little bit of Adult Care, because all it takes is 3 breaths to reconnect with yourself.
Belly Bliss offers Play+Explore classes based on your child's age though out the week and on the weekends! Visit our website for times and descriptions.


text:
When it comes to responsible investing, institutional investors and larger funds can face inertia thanks to the sheer volume of demands and expectations. However, retail investors can avoid being sucked into "greenwashed" products that cater to the lowest ESG-aligned (environmental, social and governance) denominator by focusing on the impact of their investments, WHEB Asset Management's Ted Franks recently told Nest Egg.
"There is this increasing use of this idea of impact, which is one step beyond ESG," he said.
He said that while it's tricky for larger investment products and firms to deliver responsible investment solutions, the ability for these groups to "get away with BS" is limited when faced with investors genuinely interested in impact, rather than ESG investments.
However, the semantics of the issue are where investors may stumble, Morgan Stanley's head of wealth management research Nathan Lim recognised in a recent BetaShares briefing.
Mr Lim said the point he most wanted to get across to investors was the distinction between restrictive, ESG and impact investing.
He explained: "A lot of investors or market commentators use words like ethical or ESG or impact like they all mean the same thing… but I think it's very important from an education perspective that we all must be very careful with the words that we use to describe what we're doing."
While restrictive screening, as the name suggests, screens out industries like tobacco, sugar or coal, ESG-aligned products monitor the environmental, supply-chain and ethics of their composite parts.
The next tier up on the responsible investing ladder is impact investing.
This means that the investments look beyond avoiding harm to actively seeking solutions to specific challenges like climate change, fossil fuel reliance or water scarcity.
Mr Franks gave the example of ESG-compliant Unilever which protects its supply chain, promotes transparency and monitors its environmental impact.
All of these are good things, but essentially Unilever makes ice-cream, so it's a net neutral investment.
He argued that by beginning the search for ethical investments with the end impact, investors are much more likely to build a strategy more aligned with their responsible goals.
In conversation with the Responsible Investment Association of Australia, BT Financial Group's head of customer governance and sustainability Emma Pringle said investors are increasingly expecting – rather than seeking – a baseline of responsible investment across every asset class.
"However, what we're seeing, through our conversations with our customers and adviser network, is that confusion still exists about what is (and what isn't) a responsible investment; what investors can expect from a sustainable or ethical fund, in terms of performance and also characteristics; and how to access responsible investment products," Ms Pringle added.


text:
I am often reminded of something worth reflecting upon which was mentioned by Shaykh Muhammad Saleem Dhorat in his lectures.
A group of slaves sat discussing their worth in the eyes of their master. Depending on each slave's abilities they were guessing on the price their master would put upon them. Referring to a particular slave they decided that he would get the highest price as he was the best looking, the strongest and the most hardworking among them.
This slave remained quiet however upon the insistence of the others he finally said that it was pointless their setting a price on each other. Yes, if the master himself was to set the highest price on him, then that would be worth feeling happy about.
Similarly, when admired or praised for some virtue, it is admiration and praise from other slaves of Allah ta'ala. What counts is when Allah ta'ala becomes pleased with us!


text:
2019 Craft/Goods/Service Vendor Booth
$350.00 + GST/Service Fee
Please note: Camping is NOT included in Vendor Fee. Please purchase Camping Pass separately (if required) here: Camping and Accommodations Page Jazzlo Bay Campground is highly recommended for vendors as it is just above the festival grounds. Limited spaces available!
2019 Kaslo Jazz Etc. Festival Vendor Payment
- Completed Online Vendor Application Form
- Pre-Payment of Vendor Fee online
- Damage Deposit of $100.00 Cash or Credit online
This VENDOR BOOTH INFO PACKAGE constitutes an AGREEMENT FOR SERVICE with KJES
By submitting an application you agree to conform to all the conditions and acknowledge that the Damage Deposit is held as security, and can be forfeited for non-compliance.
Services Included & Additional Charges:
- Admission for 1 staff person for 3 days is included;
- all additional staff must purchase festival admission. Please contact Vendor Coordinator for details.
- 10'x10' vending space; Every foot of frontage and depth over 10' adds $25/ft – includes hitches, service area, prep area, door access, etc. Purchasing multiple spaces is permitted.
- For example: 15' frontage X 20' depth is: $350 plus taxes (10×10 base fee) + $125(frontage) + $250(depth) = $900
- One 20 amp single outlet electrical receptacle is included
- Generators onsite are NOT permitted; pricing for other power
o Only CSA certified equipment allowed;
Conditions & Vendor Requirements:
- All vendors must be present at the festival site for a mandatory meeting with our Green Team for a 30 minute Zero Waste orientation on Thursday August 1, 2019. Details to come. Please see below for further information on our Zero Waste Policy.
- Each vendor must have a valid business license with the Village of Kaslo and provide a copy of the license by June 30th, 2019. Business licenses can be purchased through KJES for $10.00 + fees if required.
- $100.00 Damage Deposit will be held by KJES until after event. Deposit must be paid by credit card. Deposits will be returned by August 20th 2019 upon successful completion of this agreement.
- Each booth shall have at least one 5lb (minimum) ABC fire extinguisher.
- Festival Hours of Operation: Friday, Saturday and Sunday 11:00am – 11:00pm.
- Deadline for Application is May 15th, 2019. Completed applications will be notified of decision by May 31st.
- Payment of Vendor Fees is due upon Application. No Application is considered without pre-payment. Unsuccessful applications will be refunded by June 7th 2019.
- No smoking in vending or food areas – note our festival site is a non-smoking event.
- There is no refund of Vendor Fees for successful applicants after approval.
Health & Safety Requirements:
- When set up is complete, please contact the Vendor Coordinator for inspection, a checklist will be completed and signed by the vendor for our files.
Site/Setup Information:
- VENDORS MUST LOAD IN AT THEIR ASSIGNED TIME on Thursday August 1st 2019 between 8AM TO 8PM
- Site locations for booths will be maximum 10-ft frontage by 10-ft deep, unless prior arrangements are made (additional fees apply).
- All booths MUST be set up and ready to go by 10:00am on Friday. No vehicles on site after 10pm Thursday. Absolutely no exceptions.
- Vendors are responsible for their own: camping, parking, shelters, tables, chairs and other required equipment/materials
- Security Guidelines: Each Vendor is responsible for their products and possessions left on site. Vendors will not leave cash on site overnight. KJES does not provide overnight Vendor security; please discuss your needs with the Vendor Coordinator. It is strongly suggested that your booth be securely "locked" for overnight.
- VEHICLES WILL NOT BE PERMITTED TO ACCESS THE SITE AFTER 10PM THURSDAY AUGUST 1st
- Loading and unloading before and after the event by arrangement with Vendor Coordinator only.
- THERE IS NO PARKING AVAILABLE ON FESTIVAL SITE OR KASLO BAY PARK ROAD. Vendors will have to park at their camp site or make alternate arrangements.
- Vendors are required to supply and maintain at least one garbage container, one container for returnables and one container for food composting one container for paper in their booth. KJES will inspect and collect all waste from your booth throughout the weekend. Vendors not abiding by the Zero Waste Policy will risk losing their damage deposit.
- Vendors are responsible for separating and labelling appropriately: garbage, food compost, recycling. Do not use on-site festival waste stations.
- Deadline for removal of all goods from site is Monday August 5th at 12pm.
- All vendors must be "Bear Aware" and keep booth and area secure, clean and free of attractants.
Zero Waste Policy:
Our goal is to eliminate garbage going into landfills! We need your help!
The Kaslo Jazz Etc. Festival has created a Zero Waste Policy to facilitate a Green Festival! Please thoroughly read and sign the Policy and send it to the KJEF by June 30th, 2019.
Link to Zero Waste Policy: https://kaslojazzfest.com/zero-waste-policy/
This Zero Waste Policy is MANDATORY for all vendors at KJEF. Vendors are required to comply to all policy instructions clearly and thoroughly for the entirety of the festival.
Vendors who fail to comply with this Zero Waste Policy will lose their damage deposit and not be considered for future events.
- Sell items at the event in packaging that can be recycled or composted. Reduce use of disposables wherever possible.
- Please DO NOT sell items packaged in non-recyclable or non-compostable materials, for example: Polystyrene, Glass (for safety reasons), and Waxed cardboard. Recyclable plastic in our area are numbers 1, 2, 4, 5 & 7.
- Eliminate unnecessary waste items, over-packaging & products that are over-packaged.
- Correctly sort and dispose of waste, recyclables, and compostable at the event.
- Rinse clean all recyclable containers used in food preparation and use blue or clear bags for collection.
- Bring goods into the festival in cardboard or reusable boxes/containers.
The KJEF Thank you for your cooperation!
Documents to send to KJEF:
|Due Date
|Pre-Payment of FULL Vendor Fee (paid online)
|With Application
|Damage deposit (paid online)
|With Application
|Copy of Zero Waste Agreement
|June 30th
|Payment of additional charges if applicable
|June 30th


text:
Understanding Household Insurance
Understanding Household Insurance
When it comes to the subject of household insurance then it can be very confusing for the majority of people a There are many different factors that have to be taken into consideration .
Basically, there are two different types of insurance, buildings cover and contents cover.
The buildings part of insurance is taken out to safeguard the outside of the property, insurance of this type will cover you against such as damage caused by fire, storm subsidence .
When it comes to protecting and safeguarding the contents of your home then contents insurance needs to be taken .
These two types of cover can be purchased independently but in the majority of cases if you take the two out together then it can work out cheaper .
When it comes to buying household insurance the best place you can start is online, however there are many insurers out there and getting the best deal you possibly can, can be hard .
By far the best way to make sure that you get the most comprehensive cover while getting the cheapest quote is to go to a specialist broker .
a broker can do all the hard work of searching around online for you and present you with the cheapest household insurance.
One of the main reasons for going with a broker is that the majority of insurers will offer policies for household insurance that seem to offer everything but the many hidden exclusions within a policy have also expanded and if you were to have to wade through these yourself it could take forever and even then you cannot be sure of getting the cover you need.
When it comes to building insurance you will have to take into account not only your home but also such things as outbuildings, sheds, garden furniture and green house .
These are items which should be covered and you should mention any of these to your broker .
You should also make sure that the sum assured is going to cover the cost of totally rebuilding your home from scratch if need be and again here is where a specialised broker can help you come to the correct figure .
The same applies to the contents part of the household insurance, you will have to come to a figure that would replace every item that you own in your home.


text:
The Big Brother housemates have learned that either Mario or Rebecca will be evicted this week, after the nominations were revealed on Tuesday evening.
Bex looked resigned to her fate as her name was announced, nodding then smiling – but Luke did not take the news quite so well, looking stony-faced as he learned of her nomination.
Mario, meanwhile, reacted calmly to the news of his third nomination, smiling and shaking Rebecca's hand – while other housemates remained convinced another name would be announced, and looked shocked when it wasn't.
Afterwards, Bex told the others that she was convinced her time in the house was up.
"I know who's nominated me, and I think I'm going," she said. "It's the pattern."
Mario, on the other hand, was more philosophical when attempting to work out who nominated him.
Six like me, six dislike me," he told Bex, "If it went 50-50. It probably wasn't 50-50, I'd probably say it was 40-40."
"Four don't like you, four don't like me. Or seven don't like me, five don't like you. Having said that, it coulda been a mass vote."
Lisa, meanwhile, appeared relaxed after the nominations were announced – despite the possibility of being left alone in the house come Friday.
"I'm fine," she told the others, "I'm just so used to it now. It's the third time Mario's been up."
And according to the bookmakers, he may finally get his marching orders this time. According to early odds from Skybet, Mario is 8/13 to be booted from the house on Friday while Rebecca is 6/5.


text:
TOKYO (CBS.MW) -- Toyota Motor is putting foreigners at the wheel of Japan's biggest automaker.
The company said it's appointing three foreign nationals as managing directors -- the first time that non-Japanese will serve as directors at the automaker.
Toyota TM, +1.12% is internationalizing its top management to keep pace with its other globalization efforts, including overseas production and marketing.
The three foreigners are all top officials in Toyota's successful U.S. and European operations: James Press is now executive vice president and COO at Toyota Motor Sales U.S.A.; Gary Convis is president of Toyota Motor Manufacturing Kentucky; and Alan Jones is president of Toyota Motor Manufacturing (UK).
The move could pave the way for the three foreigners to be named as board members in the future.
Toyota shares (7203) dropped 10 yen, or 0.4 percent, to close at 2,640 yen on Wednesday.


text:
Additional information
|.2 lbs
Worship is the key to transformation. The greatest principle of spiritual formation is that we are changed by Jesus as we worship Jesus. Our job is to worship Jesus in all His glory, and through that the Holy Spirit will change us into the image of Christ.
Worship can take place at every moment of life, including through music. Life Action Worship is a collection of songs that helps us pay attention to Jesus and be captivated by him so that our inner being is increasingly shaped like His.
Let's worship Him together in anticipation of that Glorious Day, when His manifest presence will reign and rule in our hearts and lives.
|.2 lbs
There are no reviews yet.


text:
Long Island Muslim Society
Long Island Muslim Society (LIMS) is a not for profit religious, educational and, charitable organization. It is incorporated in the state of New York under section 501(c) of the IRS code.
The Society has established an Islamic Center at 475 East Meadow Ave, East Meadow, New York to serve the religious, educational and cultural needs of a vibrant long island community.
LIMS provides Information, consultation and counseling on religious and spiritual matters.
LIMS promotes understanding and friendship among people of all faith through its'year round interfaith programs
LIMS partners with other organizations in providing humanitarian services to people with special needs.
LIMS Milestones
LIMS incorporated as a 501(c) not for profit religious organization on August 4 1989.Three signatories: Monir Uddin Ahmed R. Ph, Lutful Hoque Chowdhury R. Ph.,
Rafiqul Islam R. Ph.
April 26 1990, Interim LIMS Executive Committee formed. A Constitution & Byelaws Committee was formed to prepare the governing rules for the organization.
December 9 1990, LIMS constitution & Bye laws adopted. An elected executive committee and a president take oath.
LIMS starts weekend Quran classes in a rental property at Hempstead Turnpike on June 9 1991.
LIMS purchases the first house on the East Meadow Avenue in December 1993 and moves all activities to this location.
LIMS purchases the second house next to the first house in the month of July 1999.
Construction for a new Islamic Center started in 2008 and completed in 2009.
LIMS purchases the third house in the month of June 2012.and builds a parking lot on the property for the Center.
The Past Presidents
Abdul Huq, Ph. D. April 1990- December 1990 (interim committee)
Muhammad Amzad Hussain, M.D. 1991-1996
Mohammed Rafiqur Rahman, R. Ph. 1997 – 2000
Mohammed Saleh, R. Ph. 2001 – 2006
Afroza Huq 2007 – 6/2009
Mohammed Rafiqur Rahman, R. Ph. 7/2009 – 3/2011
Lutful Hoque Chowdhury, R. Ph. 3/2011 – 7/2011
Mohammad Abdur Rab 7/2011 – 1/2013
Muhammad Amzad Hussain, M.D. 2/2013 – Present
Muhammad Amzad Hussain, MD, MBA 2/2013 – 12/2016
Prof. Hussain S.Ahmad, MBA, MS 2019 – Present
Activities At A Glance
LIMS provides programs for adults and children to help us learn to lead our lives spiritually and functionally as Muslims. In order to accomplish this, the following are our present activities:
Daily 5 Prayers
Friday Jummah Prayer
Weekly Children and Adult educational programs
Participation in Inter-faith dialogue and events.
Partnership with the Long Island local churches, synagogues, local charities and Interfaith Nutrition Network (INN) to donate food to feed the hungry.
Support Kiwanis Club of East Meadow for distribution of food during the Thanksgiving holiday.
Provide Annual Blood Drive
Clothes and blanket donation to poor and needy during winter.
School Supplies to needy communities.
Monetary donations to Refugees around the world.
Financial Aid workshop for HS Seniors
Educational Seminars.


text:
Collar of the President of Ukraine
This article does not cite any sources. (February 2014) (Learn how and when to remove this template message)
The sign (collar) of the President of Ukraine weighs about 400 grams. President's collar is not obligatory, but most European heads of state have such a decoration: for instance, the President's collar (male jewelry like a female necklace) is one of the symbols of state power in Poland, the Czech Republic, and Bulgaria. Some countries grant another collar to new head of the state, and the previous one passes to the national museums. An open-work chain with a historical relic – an amulet which, as the legend reads, belonged to Ukrainian Hetman Ivan Mazepa – was among the attributes of the President of Ukraine (in exile).
The collar is made of white and yellow gold. Kiev artists have painted its seven medallions. They represent miniatures of Vladimir the Great's Trident, the coat of arms of the Kingdom of Galicia–Volhynia and that of the Grand Duchy of Lithuania, "The Cossack with a Musket" sign, Hetman Bohdan Khmelnytsky's patrimonial Syrokomla coat of arms and the Ukrainian People's Republic's coat of arms as the first attempt to establish independent Ukraine in the 20th century. The painted medallions alternate with jewelry ones: above laurel wreathes of white gold there are guelder rose leaves of yellow gold gemmed with 96 garnets each one and a half millimeters.
Both, the seal and the collar are kept in leather cases with the velvet lodgement and the imprinted image of the lesser Emblem of Ukraine.
|This article relating to Ukraine is a stub. You can help Wikipedia by expanding it.


text:
2018 Hyundai Sonata /vs/ 2018 Honda Accord
If you're looking for a new sedan that meets your high expectations, then chances are you've done a lot of research and found the 2018 Hyundai Sonata and the 2018 Honda Accord. Both of these vehicles have a lot of features that consumers are searching for, but if you're looking for a bit more from your vehicle's engine as well as a hands free auto-opening trunk, then you should check out the new Sonata. Keep reading to see how these sedans actually stack up.
Compare To The Competition
2018 Hyundai Sonata
- 2.4-liter 4 cylinder engine
- 6-speed automatic transmission
- Standard AUX port
- Bluetooth Compatibility
- Standard Voice Recognition
- Available Navigation System
- Available Sport Seats
- Available Heated and Cooled Front Seats
- Available Hands Free Auto-Opening Trunk
- Available Parking Assist
- Available sunroof
2018 Honda Accord
- 1.5-liter 4 cylinder engine
- 2-speed CVT
- AUX port (not available)
- Bluetooth Compatibility
- Voice Recognition (not available)
- Available Navigation System
- Bucket Seats
- Available Heated and Cooled Front Seats
- Hands Free Auto-Opening Trunk (not available)
- Available Parking Assist
- Available sunroof
If you're interested in becoming the proud owner of a 2018 Hyundai Sonata, give us a call, or stop by our dealership at 1950 Tamiami Trail, Punta Gorda, FL 33950 for a test-drive today. We look forward to serving our customers near Port Charlotte, North Port, Venice and Fort Myers.


text:
You are not logged in.
Dear visitor, welcome to Allods Online Forum. If this is your first visit here, please read the Help. It explains in detail how this page works. To use all features of this page, you should consider registering. Please use the registration form, to register here or read more information about the registration process. If you are already registered, please login here.
Thursday, July 18th 2019, 5:23pm
Monday, July 2nd 2018, 3:10pm
Wednesday, June 20th 2018, 10:54am
Friday, May 16th 2014, 7:27pm
Saturday, May 10th 2014, 7:22pm


text:
In mid-October, 2013 ended the third consecutive expedition. It is managed by V. Gyorev with participants A. Genkov and K. Stoichkov (Bulgaria),I. Agapov, S. Kaminski (Russia), G. Lazaridis, L. Makrostergios, A. Radulesko (Greece), D. Tomich (Serbia). Researchers expanded the perimeter of studies, covering territories around the monasteries Hilendar, Esvigmen, the Great Lavra, the Romanian Skete Timiou Prodromou, Athos summitand the place Virgin Mary (Panagia) below the peak.
There are found and mapped 26 new underground sites (mostly caves), among which is the longest explored cave of the peninsula up to date in Karulya place (length about 130 m). It was explored also the so called Athos Large Cave, which recently is the biggest in volume cave on the Athos peninsula.
They're found and located with GPS receivers, finding 20 more cave entrances but because lack of time they were not surveyed! The total length of the surveyed sites together with the caves which exploration is in progress.


text: Issue 94 of Eye magazine has been released with 8000 unique covers designed by MuirMcneil. August 30, 2017 #TYPE DESIGN, TECHNOLOGY, PUBLISHING MuirMcNeil, its nice that, Eye Magazine Share this post to: Next post:A font deck Or back to all posts The type special, uses two typefaces, TwoPoint and TwoPlus, and HP Mosaic technology to create the individual covers. Newer:Process and Place with type designer Maciej PolczynskiOlder:A font deck PostedAugust 30, 2017 AuthorNicole Phillips CategoriesTYPE DESIGN, TECHNOLOGY, PUBLISHING TagsMuirMcNeil, its nice that, Eye Magazine


text:
Global Business and the Terrorist Threat
Edited by Harry W. Richardson, Peter Gordon and James E. Moore II
Chapter 4: Assessing, Managing and Benefiting from Global Interdependent Risks: The Case of Terrorism and National Disasters
Howard C. Kunreuther and Erwann O. Michel-Kerjan
4. Assessing, managing and benefiting from global interdependent risks: the case of terrorism and natural disasters Howard C. Kunreuther and Erwann O. Michel-Kerjan INTRODUCTION With the increasing globalization of economic and social activities, the world has now become so interdependent that actions taken today 5000 miles away could affect you tomorrow. Conventional wisdom holds that one country or one organization has the capacity and expertise to manage future large-scale risks alone. However, in an increasingly global interdependent world, they have neither. A hallmark of the twenty-first century is that we have entered a new era of catastrophic risks, as illustrated by the evolution of economic and insured losses associated with a series of global events that occurred in just the past few years. The increase in insured losses from man-made (including terrorism) and natural disasters worldwide since 1970 (see Figure 4.1) graphically depicts the new era we have entered. From Table 4.1 we see that the 9/11 terrorist attacks inflicted $35 billion in insured losses.1 Claims were paid by over 150 insurers and reinsurers worldwide, illustrating how risks are today diversified over global markets. Four major hurricanes hit one of the most populated states in the US (Florida) in 2004, and three major hurricanes hit the Gulf of Mexico the following year. The devastation due to Hurricane Katrina in 2005 was unprecedented both in terms of human and economic losses. It is the most costly catastrophe in the history of insurance worldwide ($46.3 billion in insured losses) as shown in...
You are not authenticated to view the full text of this chapter or article.
Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.
Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.
Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.


text:
broken up
my dear love nick green posted a really excellent blog post about playing hard to get and it made me think instantly of a recent series of breakups-well, sort of breakups because you can't really "breakup" when there isn't anything to break up but it's still the end of a "relationship" so breakup really seems like the best word and it's all just really confusing and at the end of the day you really know it's all for the best and that your life will be better without these people in it and yeah that sounds selfish but whatever i gotta look out for number one and yes i did say people rather than person don't judge me monogamy is a social contract and not a given...
so yeah, we broke up.
anywho, the thing that i find so interesting about these breakups is that i am in no way sad about them but when they go unacknowledged i feel sort of put out and then i get sad about the breakup. is it the breakup or the acknowledgement of the breakup that makes it real when it wasn't particularly real to begin with?
(am i writing an episode of sex and the city here?)
an example: brad* and i have known each other for a little shy of two years. we met online a bit before i left calgary and weren't able to ever actually meet up. i've obviously been in calgary a number of times since then and for whatever reason we still haven't managed to cross paths. we were both pretty stoked at the idea of my being in this fair-ish city for a couple months and had a standing date for coffee**. 20 months is, afterall, a long time for just texting. but here's the thing about brad, i actually have no memory of what he looks like and no concept of who he really is a person and i've never known his last name. this may all seem sort of silly but for these and a host of other reasons*** i decided not to see him. and whatever, that happened and i am not sad about it.
but here's the thing, i got sad because he didn't write me back. we want a fight don't we? someone to tell us to fuck off or make us feel guilty or beg us for something more, beg us to hang on to them... it feels weird to just toss it out into the ether and get back... silence. maybe that silence speaks louder than any response but i wanted a response. i wanted a fight. or at least i wanted brad to tell me to go fuck myself... or something.
maybe i just don't know what the fuck i want.
*i picked brad because then i can pretend that i broke up with brad pitt.
** and other such things.
*** none of your goddamn business


text:
Let me start this by saying that day 2 of the 3 day potty training program sucked great big hairy monkey balls.
Andy seemed to be having even more accidents than the first day and I was constantly cleaning. The only thing I was doing more often than cleaning was telling Andy to tell me when he needed to potty. He was ignoring me. We were both stir crazy from being in the house for so long. It was ugly. It was miserable. I couldn't believe that I was spending my fall break this way. In fact, I even had to clean up a mess after Molly. I prayed that I would do a better job with Andy than I have with Molly.
Day 3 rolled around, and Andy woke up dry after sleeping for 5 hours. Accidents were still fairly prevalent. Andy was still tired of me telling him to tell me when he had to go potty. I spent huge amounts of time cleaning up after accidents. In a panic I re-read the book. And I found some solace. Everything that Andy was doing was totally typical. I just needed to stay the course and keep being positive, full or praise and consistent. Brian had begun to doubt me, so I had him do some reading as well.
I kept thinking that part of the trouble might be that Andy has had a cough and a little cold. At midnight last night he woke up crying and coughing. We went to him expecting to find him wet and cold. Instead, he was dry. We brought him to the potty and he went. I easily put him back to bed. This morning Andy woke up around 8:00. Totally and completely dry! A few minutes later he asked to go potty, and he went.
It's now 1:30. Andy is napping. There have been no accidents. He's still wearing the same underpants I put him in after his bath last night. I'm hopeful.
Random ramblings of life in our household . . . and our journey through infertility and our arrival on the other side as we live life with our precious little boy brought to us through the gift of open domestic adoption.
Friday, October 22, 2010
PT Days 2 & 3, and Into 4
Labels: Totally Toddler
4 comments:
Subscribe to: Post Comments (Atom)


text:
Product Description
Lessons on Loss
Don't just scratch your head and throw up your hands in despair! Check out the new family of Balanced Living Health Tracts (additional series titles will be added soon), attractively priced at just $5.50 per pack of 50.
Lessons on Loss
Loss is a part of life—the hardest part. How can I learn to deal with the inevitable loss, grief, and pain that occur in life and come out better on the other side of it? Lessons on Loss shows you how.
Have you ever found yourself sitting in a Health Presentation wanting to take notes, but had nothing to do it on? Hamblin's HOPE is excited to introduce the New, Larger Health Tracts, available in all 24 lessons. You will receive the same great, life – changing information as you do in the smaller, pocket-sized tracts with an added bonus…the ability to take notes and make life – improving healthy living goals! Great for small group settings, Health Nuggets during Evangelistic Meetings, as well as any LifeStlye Matters Seminar or Cooking School! Order yours today!
Minimum Quantity Required: 1
$5.00 each


text:
Monday, March 9, 2009
Randy Pausch's Teaching Techniques S09JSM602
Keith Grace and Kimberly Bass discuss "The Last Lecture of Randy Pausch" and describe his teaching and learning techniques. In his "last lecture" titled "Really Achieving Your Childhood Dreams" Randy gave us numerous examples of his teaching techniques and his own personal learning experiences even though his lecture was not explicitly dealing with these topics. Randy was a Professor at Carnegie Mellon. If you have not listened to or watched Randy's "Last Lecture", we strongly urge you to do so. You can find a link to the YouTube video of Randy's lecture on the Carnegie Mellon University site.
Subscribe on iTunes or LISTEN HERE.
Posted by John Hadley Strange at 7:10 AM
Subscribe to: Post Comments (Atom)


text:
Sold Out $18,399.00
Designed for those with a need to speed, the Predator 17 gaming notebook combines powerful 6th Gen Intel Core processor with high-performance NVIDIA GeForce graphics to ensure powerful performance and astounding gaming experiences. Advanced cooling and stellar audio capabilities support intense gaming sessions while the sporting red accents and black chassis with geometric lines adds to the drama.
The Acer Predator 17 Notebook was designed with bold highlights, confident angles and dynamic geometry. The colorful red accents create a dynamic visual effect and represent passion and speed. The supercharger inspired air exhaust vents look bold from every angle while the red LED light bar glows while the graphic card is working.
Inside the Predator ProZone backlit keyboard glows in red and aids gamers when gaming in dimly lit rooms. Its spacious keyboard features four customizable backlight zones and features programmable keys. A number pad and dedicated macro buttons give every gamer the control they deserve.
Acer pushes the limits of in-game audio with Predator SoundPound, a combination of stellar audio features including four speakers, two subwoofers and Dolby Audio surround sound delivering superior sound and an immersive surround experience that is rich and clear. In addition, Predator's True Harmony Premium fine-tunes and improves the frequency balance to deepen the impact of movies, games and music.
Dominate your gaming competition with an unleashed and uncompromised processor. With a killer combination of smart features, the 6th gen Intel Core i7 processor is flexible and devastatingly powerful. It's the ultimate weapon when you demand unrivaled PC performance for gaming at its best—because the only thing more amazing than Intel technology is what you'll do with it.
The latest NVIDIA GTX 980M graphics delivers blazing-fast performance and futuristic, visually-stunning graphics to your games and movies. Now you can take on your PC games with faster, smoother gameplay at ultra-settings.
We could all use a little less lag. With Killer DoubleShot Pro your Ethernet and Wi-Fi to work together for the ultimate high speed attack. You choose which applications get to use your precious bandwidth for the best possible networking experience.
The Predator notebook features the PredatorSense gaming control panel, providing customization and control of gaming features, including macro programmable keys for up to 15 in-game shortcuts and adjustable lighting controls.
Unleash your entertainment with the impressive 17.3-inch Full HD Widescreen IPS Display with a true 16:9 cinematic format. From game play to watching a movie, you'll see all the action in consistent, clear color, even from wide viewing angles. Enjoy support of up to three monitors, including one monitor with support for NVIDIA G-SYNC technology.
Keep your new rig nice and clean with Predator Dust Defender. Alternating airflow directions help stop dust from building up and maintain a cool temperature, which ensures your high-end components will keep running smoothly. For extreme gamers who need to keep their notebook operating at lower temperatures, inject some cold to keep heat down and performance up with Predator FrostCore. Prepare for intense gaming sessions by placing the Acer exclusive extra Cooler Master fan in the optical disk drive bay for additional air flow.
With the HD Webcam and Skype for Business Certification with Windows 10, you can call, video chat, message, and share files seamlessly with superior audio and visual quality. Connect with friends across the web and enjoy crystal clear and instant communications without echoes, gaps or lags.
Gaming just got even better with Windows 10. Not only do your existing games work great, but now you can play and connect with gamers across your Predator Notebook and Xbox One. From the best casual games to a new generation of PC gaming, Windows 10 is built for the games you love.


text:
What the brand says: DearPacker is professional Korean brand introducing skin care products that transform your skin giving you beautiful, flawless complexion! This brand has formulated these sheet masks exclusively for Nykaa under the range called as 'home remedy' that consists all the natural ingredients we Indians love using.
Packaging: The sheet masks come in a pretty colorful plastic packets (with ingredients printed on it) that need to be peeled off to remove the sheet mask soaked in essence.
My take on respective 'Home Remedy' sheet masks:
Coconut- This particular sheet mask claims to keep your skin soft, supple and glowing. This sheet mask is drenched in essence that has nourishing properties with the goodness of coconut extracts. The very first thing that came to my mind was Bounty chocolate when I opened the packet; it smells super delicious! The sheet mask does not feel watery and the essence seems quite thick. Also, this is the first mask ever that physically fitted me so well! This should be the case with all the other sheet masks to (That we'll see!). I let the sheet mask work for good 30 minutes, peeled it off and massaged the remaining essence into my skin. It got completely absorbed and made my skin matte and super soft at the same time. I usually wash off the sheet masks because of the sticky feeling but this one felt super light on the skin once it got absorbed. You can even put on your makeup or follow with your skin care routine! This mask need not be only used at night, you can use it during the day time too since it doesn't feel sticky like the innisfree sheet masks (in my opinion). Now coming to the claims, this mask does soften and smoothen your skin so I give this a thumbs up!
Rating: 5/5
Turmeric and Yogurt- This particular sheet mask claims to give you a brighter, clearer and glowing complexion. This sheet mask is drenched in essence that has turmeric and yogurt extracts that provides moisture and nutrition to tired, dull skin. The mask smells of turmeric essential oil which is very mild and not strong at all. I was expecting the mask to have a hint of yellow color since it has a potent staining ingredient- turmeric (even turmeric essential oil or its extract is yellow!) but to my surprise, the mask is soaked in clear viscous liquid. This mask too fits really well and covers the nicks and corners of the face. I let the sheet mask work for good 30 minutes, peeled it off and massaged the remaining essence into my skin. The mask took a bit longer to get absorbed than the earlier mask I used but once it was completely absorbed, it was matte and skin felt clean. Skin felt a bit brighter and softer but results are not miraculous! I can get similar brightness/glow and softness after exfoliating or cleansing my skin! Skin does feel fresh but that isn't the only thing I expect from this mask. I feel homemade turmeric and yogurt mask works 100 times better and this certainly cannot be an alternative!
Rating: 2.5/5
Charcoal- This particular sheet mask claims to cleanse your pores by drawing out all the impurities, clear up your blemished skin, absorb excess sebum, purify skin and tighten the pores. The sheet has charcoal extracts that has great adsorption properties (we all are aware of it!) which makes it a great skin purifying ingredient! Unlike other masks, this sheet mask is actually black in color because it is made up of exclusive blend of bamboo charcoal and bamboo fiber woven together to perfection. The sheet mask smells of fake fragrance obviously because charcoal doesn't smell of anything and the ingredients depicts fragrance added to it! This mask too fits really well and covers the nicks and corners of the face. I let the sheet mask work for good 30 minutes, peeled it off and massaged the remaining essence into my skin which got dry and matte in no time. Skin felt very smooth and firm and I do feel very clean! Excess sebum is definitely absorbed because there isn't any shine even after an hour! Since my skin feels very clean and fresh, I am sure the charcoal has done its job of drawing out all the impurities. I do not have visible open pores but I do have enlarged pores because of acne scarring and just a face mask won't help it; but my skin does feel firm so I am sure this will work for open pores (enlarged and open pores isn't the same)! Regarding the skin clearing claim, that is something one cannot expect from just one use and reusing this multiple times (not to forget each use costs 100 bucks!) will burn a hole in your pocket. I would use an actual activated charcoal powder instead for that price which should last for more than a year! The mask is great when you want to cleanse your pores and purify your skin!
Rating: 4.5/5
Green Tea and Jasmine- This sheet mask claims to sooth irritated skin, reduce redness and improve the overall appearance of complexion. Jasmine has soothing and calming properties while green tea reverses UV damage and improves the complexion. The mask smells floral and the fragrance is very mild. I used the sheet mask just like I used the others and this one too fits really well on the face. After using the mask, I massaged in the essence and it dried up in no time leaving behind a velvety-matte feel to the skin which definitely looked healthy. My skin definitely felt fresh and brightened up! It did improve the complexion (and when I realized this I did not even know what the sheet mask claims). I have 2 active tiny blemishes on my nose and forehead and they definitely seemed calmed down, felt less painful and redness was visibly reduced; and guys this did happen I am not even kidding you! The mask is great to reduce any redness and inflammation of the skin and to my surprise the effects were seen from just one usage. I now want to grab more of this one to regularly use it, as 4 out of 10 days, my skin is inflamed due to blemishes! I give this mask a thumbs up!
Rating- 5/5
Fenugreek and Cucumber- This sheet mask claims to cool your skin and reduce any rashes or inflammation. The fenugreek and cucumber work as cooling agents and reduce suntan, rashes and any inflammation on the skin. I used the sheet mask just like I used the others and this one too fits really well on the face. After using the mask, I massaged in the essence and it dried up in few minutes leaving behind a velvety-matte feel to the skin which definitely looked healthy. I used this when I was back home and skin felt fresh, cooled down and healthy. I do not have any tan yet so cannot comment on the anti-tan effects. October is getting hotter and this mask worked great in keeping my skin calm! For added benefits, keep the mask in fridge for an hour before using it to enhance the cooling and calming effects. There isn't any miraculous visible effects or changes but you can definitely feel your skin better and not-as-inflamed as it gets on a hot day. You can definitely get more of these and stock up in the fridge to use throughout October or summer season. I quite like this mask and give this a thumbs up.
Rating- 4/5
Cinnamon and Honey- This sheet mask claims to correct visible signs of aging, lift and nourish your skin. The cinnamon has skin tightening effects while honey nourishes. I used the sheet mask just like I used the others and this one too fits really well on the face. After using the mask, I massaged in the essence and it dried up in few minutes leaving behind a velvety-matte feel to the skin which definitely looked healthy. I do not have saggy or wrinkled skin as i am still in my 20s but my skin did feel tighter and healthy. Also, after massaging in the essence, skin looked brightened up maybe because of honey since it works as a natural bleaching agent. Skin felt soft and smooth and I applied my makeup without even rinsing off the essence and my skin felt very healthy and nourished. The mask does work and I give this a thumbs up!
PRICE: INR 100 each/-